HONG KONG – Glaxosmithkline plc confirmed it will be shutting down operations at its Neuroscience R&D Centre in Shanghai. The U.K.-based pharmaceutical giant will move key programs to the global R&D hub in the U.S. "following a portfolio review and prioritization," as outlined in a statement.
HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. signed a collaborating agreement with the National Cancer Center of Japan to join forces in developing rare cancer cures and genomic medicines.
HONG KONG – Glaxosmithkline plc confirmed it will be shutting down operations at its Neuroscience R&D Centre in Shanghai. The U.K.-based pharmaceutical giant will move key programs to the global R&D hub in the U.S. "following a portfolio review and prioritization," as outlined in a statement.
HONG KONG – To speed up biopharmaceutical research on fighting superbugs, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) recently awarded grants to a number of biopharma firms, among them a 3-year-old startup aptly named Bugworks Research India Pvt. Ltd., which received $2.6 million.
HONG KONG – To speed up biopharmaceutical research on fighting superbugs, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) recently awarded grants to a number of biopharma firms, among them a 3-year-old startup aptly named Bugworks Research India Pvt. Ltd., which received $2.6 million.
